AxoGen (NASDAQ:AXGN) Stock Price Target Raised at HC Wainwright

Key Points

• HC Wainwright raised AxoGen’s price target from $53 to $56 while maintaining a “buy” rating, implying 13.71% upside. The analyst consensus is “Moderate Buy,” with an average target of $55.55.
• AxoGen’s latest quarter exceeded expectations, reporting EPS of $0.21 versus the $0.13 consensus and revenue of $75.83 million versus estimates of $73.18 million.
• Shares have rallied sharply, trading near their 12-month high, but the company remains unprofitable and insiders sold approximately $4.66 million of stock over the past 90 days.

AxoGen (NASDAQ:AXGN - Get Free Report) had its target price lifted by HC Wainwright from $53.00 to $56.00 in a report released on Thursday, Marketbeat.com reports. The firm presently has a "buy" rating on the medical equipment provider's stock. HC Wainwright's price target indicates a potential upside of 13.71% from the stock's previous close.

Several other research analysts have also recently issued reports on the company. Barclays reaffirmed an "overweight" rating and issued a $60.00 price target on shares of AxoGen in a report on Thursday. Bank of America began coverage on AxoGen in a research report on Monday, October 12th. They issued a "buy" rating and a $52.00 price target for the company. Morgan Stanley downgraded AxoGen to a "hold" rating in a research note on Tuesday, September 29th. Truist Financial cut their price objective on AxoGen from $60.00 to $53.00 and set a "buy" rating for the company in a report on Thursday, October 1st. Finally, Canaccord Genuity Group lifted their price target on AxoGen from $50.00 to $55.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $55.55.

AxoGen Trading Up 31.5%

Shares of NASDAQ:AXGN opened at $49.25 on Thursday. The company has a 50 day moving average of $42.78 and a 200-day moving average of $39.28. The firm has a market cap of $2.65 billion, a P/E ratio of -72.43 and a beta of 1.17. AxoGen has a twelve month low of $18.46 and a twelve month high of $52.91. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07.

AxoGen (NASDAQ:AXGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.08. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.18 million. As a group, analysts anticipate that AxoGen will post -0.44 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Marc A. Began sold 67,500 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the transaction, the executive vice president owned 50,135 shares in the company, valued at approximately $2,373,390.90. The trade was a 57.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 98,503 shares of company stock worth $4,656,947. Corporate insiders own 2.44% of the company's stock.

Hedge Funds Weigh In On AxoGen

Institutional investors and hedge funds have recently modified their holdings of the business. State of Alaska Department of Revenue boosted its holdings in shares of AxoGen by 16.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider's stock valued at $118,000 after purchasing an additional 409 shares in the last quarter. PNC Financial Services Group Inc. increased its position in AxoGen by 6.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider's stock worth $296,000 after purchasing an additional 525 shares in the last quarter. Nykredit A S acquired a new stake in AxoGen in the second quarter valued at approximately $30,000. Arizona State Retirement System grew its stake in shares of AxoGen by 7.6% during the second quarter. Arizona State Retirement System now owns 13,604 shares of the medical equipment provider's stock worth $628,000 after buying an additional 966 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of AxoGen by 1.4% during the first quarter. Principal Financial Group Inc. now owns 89,745 shares of the medical equipment provider's stock worth $2,973,000 after buying an additional 1,210 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen News Summary

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Third-quarter earnings beat expectations: AxoGen reported adjusted earnings of $0.21 per share, above the $0.13–$0.14 analyst consensus and up from $0.12 a year earlier. Revenue rose to $75.83 million, exceeding estimates of approximately $73.18 million. AxoGen Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Full-year guidance was raised: Management now expects at least 29% revenue growth, or approximately $290 million in 2026 revenue. The increased outlook reinforces the market’s view that AxoGen is sustaining strong sales momentum. AxoGen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Investor momentum strengthened: Trading volume in AXGN call options surged, with 9,886 contracts purchased versus average daily volume of about 900. While options activity does not guarantee future gains, it signals heightened bullish speculation following the earnings release.
• Neutral Sentiment: Management commentary provided additional context: The earnings presentation and conference call are likely to receive close attention as investors assess the durability of growth and the company’s path toward consistent profitability. AxoGen Q3 2026 Earnings Call Transcript
• Negative Sentiment: Valuation and profitability risks remain: Despite the earnings beat, AxoGen continues to report a negative net margin and negative trailing price-to-earnings ratio. After the sharp rally, some market commentary questioned whether the stock’s improved outlook is already reflected in its price, increasing the risk of profit-taking or volatility.

About AxoGen

AxoGen, Inc NASDAQ: AXGN is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company's product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient's body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.